---
title: "Apogee Therapeutics CEO Michael Thomas Henderson disposes of USD 2.67 million in common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292363300.md"
description: "Apogee Therapeutics CEO Michael Thomas Henderson sold shares, reducing his stake. On July 8, he sold 20,000 shares at $133.63 each. On July 10, he disposed of 75,046 shares in a transaction reported at $0. Following these transactions, Henderson holds 920,941 shares."
datetime: "2026-07-11T00:01:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292363300.md)
  - [en](https://longbridge.com/en/news/292363300.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292363300.md)
---

# Apogee Therapeutics CEO Michael Thomas Henderson disposes of USD 2.67 million in common shares

-   Apogee Therapeutics CEO Michael Thomas Henderson cut his stake through a 20,000-share sale on July 8 at USD 133.63. \* He also disposed of 75,046 shares on July 10 in a transaction reported at USD 0. \* Henderson reported 920,941 shares owned following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-082758), on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)

## Related News & Research

- [Apogee Therapeutics CMO Carl Dambkowski sells 5,500 common shares worth $730,070](https://longbridge.com/en/news/291600683.md)
- [Apogee Therapeutics CEO Michael Thomas Henderson sells 80,000 shares for $10.6 million](https://longbridge.com/en/news/290751491.md)
- [Bicara Therapeutics director Christy J. Oliger files initial beneficial ownership statement](https://longbridge.com/en/news/294255131.md)
- [Scribe Therapeutics CFO David Parrot reports $ 39,990 common stock acquisition](https://longbridge.com/en/news/293991409.md)
- [Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, files initial beneficial ownership statement](https://longbridge.com/en/news/293969051.md)